RM-IMM / Immune and host-defense signaling
Thymosin alpha 1
Also known as: Thymalfasin · Talpha1 · Zadaxin
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Thymosin alpha 1 is a defined 28-amino-acid peptide derived from the thymosin alpha precursor. The literature includes mechanistic work, reviews and human trials across several immune-related settings. Those records must stay separated by indication and formulation.
Evidence position
Human trials exist, but the record is mixed and context-specific. A published trial is evidence about its studied intervention, not proof of purity, identity or performance for a retail sample.
What the record does not establish
No paper, review or supplier certificate substitutes for a matched lot identity, quantity, purity and microbiological record.
Sources
- 01Thymosin alpha 1: A comprehensive review of the literaturePubMed
- Shows
- Review of the molecular and clinical literature
- Does not show
- A review does not authenticate a marketed sample or establish broad clinical effectiveness
- 02TESTS phase 3 randomized trialPubMed
- Shows
- Large controlled human trial that found no clear mortality benefit in the studied sepsis population
- Does not show
- One indication, dosing program and finished investigational presentation
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Thymalfasin
- CID
- 16130571
- Formula
- C129H215N33O55
- Mass
- 3108.3
PUBMED / FOUND RECORDS
- Thymosin alpha-1.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists / 2001 May 15PMID 11381492 / DOI 10.1093/ajhp/58.10.886
- Aging and Thymosin Alpha-1.International journal of molecular sciences / 2025 Nov 27PMID 41373628 / DOI 10.3390/ijms262311470
- Thymosin alpha-1 treatment in chronic hepatitis B.Expert opinion on biological therapy / 2015PMID 25640173 / DOI 10.1517/14712598.2015.1007948
- beta-Thymosins.Annals of the New York Academy of Sciences / 2007 SepPMID 17468232 / DOI 10.1196/annals.1415.018
- Clinical applications of thymosin alpha-1.Cancer investigation / 1994PMID 7922712 / DOI 10.3109/07357909409021415
CLINICALTRIALS.GOV / FOUND RECORDS
- Thymosin-α1 for Recurrent Implantation FailureRECRUITING / PHASE2, PHASE3 / Fakih IVF Fertility CenterNCT07675980 / DIRECT intervention MATCH: Thymosin alpha 1
- Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected PatientsCOMPLETED / PHASE1, PHASE2 / Replicor Inc.NCT02646189 / DIRECT intervention MATCH: Thymosin alpha 1
- Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 InfectionTERMINATED / PHASE2 / Rhode Island HospitalNCT04487444 / DIRECT intervention MATCH: Thymosin alpha 1
- Zadaxin and HIV-positive Patients With Immune Reconstitution DisorderCOMPLETED / EARLY_PHASE1 / Shanghai Public Health Clinical CenterNCT04963712 / DIRECT intervention MATCH: Thymosin alpha 1
- SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line ChemotherapyUNKNOWN / PHASE2 / The First Affiliated Hospital of Xiamen UniversityNCT02976740 / DIRECT title MATCH: Thymosin alpha 1